Výsledky vyhledávání - "Bernard E. Ilson"

Steady-State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure

Autor: Duane A. Boyle, Susan C. Brozena, Diane K. Jorkasky, Henry F. Fesniak, Bernard E. Ilson, David Tenero, Steven C. Boike

Publikováno v: The Journal of Clinical Pharmacology. 40:844-853

Carvedilol is a relatively new drug with beta- and alpha 1-receptor blocking activity and antioxidant effects recently approved for the treatment of congestive heart failure (CHF). An ascending, multiple-dose study was completed in 20 male patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e20631c00a43e8400ab301f1b2ef8c93
https://doi.org/10.1177/00912700022009576

Zobrazit plný text záznamu

Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: Effects on the regulation of renal vascular tone

Autor: Robert Z. Harris, Bernard E. Ilson, Diane K. Jorkasky, Douglas E. Wilson, Martin I. Freed, Kathleen A. Thompson

Publikováno v: Clinical Pharmacology & Therapeutics. 65:473-482

Objective To evaluate the pharmacokinetics and pharmacodynamics of an infusion of SB 209670, a nonpeptide endothelin-A/endothelin-B receptor antagonist. Methods The study was conducted in 2 parts. Part 1 was a placebo-controlled, single-blind, rising

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08abec14c0e9c46b4e0e7539c5bfaf7
https://doi.org/10.1016/s0009-9236(99)70066-4

Zobrazit plný text záznamu

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food

Autor: Névine Zariffa, Bernard E. Ilson, David E. Martin, David Lundberg, Steve Boike, Duane A. Boyle, Diane K. Jorkasky, John Jushchyshyn, David Tenero

Publikováno v: Biopharmaceutics & Drug Disposition. 19:351-356

Eighteen healthy males received a single 300 mg oral dose of eprosartan as the commercial wet granulation formulation under fasting conditions and following a high-fat breakfast and a single 20 mg intravenous (i.v.) dose. The pharmacokinetics of i.v.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::139bb8e8ec7eabf5e0f713858362832a
https://doi.org/10.1002/(sici)1099-081x(199809)19:6<351::aid-bdd115>3.0.co

Zobrazit plný text záznamu

Effect of age and gender on the pharmacokinetics of eprosartan

Autor: David E. Martin, David Tenero, Diane K. Jorkasky, Bernard E. Ilson, Ann K. Miller, Steven C. Boike, Névine Zariffa

Publikováno v: British Journal of Clinical Pharmacology. 46:267-270

Aims To compare the pharmacokinetics of eprosartan between young (18-45 years) and elderly (65 years) men and between young men and young, premenopausal women (18-45 years). Methods Twenty-four subjects (eight subjects/group) received a single 200 mg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05309f9bdfe5d64ea4e8e90a008f4970
https://doi.org/10.1046/j.1365-2125.1998.00778.x

Zobrazit plný text záznamu

Eprosartan Does Not Affect the Pharmacodynamics of Warfarin

Autor: Alan Forrest, Bernard E. Ilson, David E. Martin, Névine Zariffa, David J. Kazierad, Diane K. Jorkasky, Steven C. Boike

Publikováno v: The Journal of Clinical Pharmacology. 38:649-653

Eprosartan is an angiotensin II receptor antagonist being developed for the treatment of hypertension and heart failure. The effect of eprosartan on the steady-state anticoagulant activity of warfarin was evaluated in 18 healthy male volunteers. Each

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb880588f9011c03667e0ef60b59d68a
https://doi.org/10.1002/j.1552-4604.1998.tb04473.x

Zobrazit plný text záznamu

The Effects of Eprosartan, an Angiotensin II AT1Receptor Antagonist, on Uric Acid Excretion in Patients with Mild to Moderate Essential Hypertension

Autor: Bernard E. Ilson, Steven C. Boike, Diane K. Jorkasky, David E. Martin

Publikováno v: The Journal of Clinical Pharmacology. 38:437-441

The effects of antihypertensive agents, including angiotensin II receptor antagonists, on urine uric acid excretion may have important clinical consequences. Therefore, the effects of single and repeated doses of eprosartan on uric acid excretion wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a18ad32c9fd1799c19f0c03e5eb77898
https://doi.org/10.1002/j.1552-4604.1998.tb04450.x

Zobrazit plný text záznamu

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men*

Autor: Steven C. Boike, Martin I. Freed, Bernard E. Ilson, David E. Martin, Diane K. Jorkasky, Névine Zariffa

Publikováno v: Clinical Pharmacology & Therapeutics. 63:471-481

Study design The effects of orally administered eprosartan on changes induced by angiotensin II in blood pressure, renal hemodynamics, and aldosterone secretion were evaluated in healthy men in this double-blind, randomized, single-dose, placebo-cont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1977d4fe4f3fbde5cd423a25d408a3a
https://doi.org/10.1016/s0009-9236(98)90043-1

Zobrazit plný text záznamu

Effect of Ranitidine on the Pharmacokinetics of Orally Administered Eprosartan, an Angiotensin II Antagonist, in Healthy Male Volunteers

Autor: Bernard E. Ilson, Duane A. Boyle, David Tenero, Steven C. Boike, David Lundberg, Alison M Carr, David E. Martin, Diane K. Jorkasky

Publikováno v: Annals of Pharmacotherapy. 32:304-308

OBJECTIVE: To assess the effect of ranitidine on the pharmacokinetics of eprosartan in healthy male volunteers. DESIGN: Single-center, randomized, open-label, two-period, period-balanced, crossover study. PATIENTS: Seventeen healthy men aged 19 to 43

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e05a718c2ad12dd8f9474cf85bdf61cc
https://doi.org/10.1345/aph.17188

Zobrazit plný text záznamu

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*

Autor: Robert A. Blum, David J. Kazierad, Diane K. Jorkasky, Rickey C. Etheredge, David E. Martin, David Tenero, Steven C. Boike, Bernard E. Ilson

Publikováno v: Clinical Pharmacology & Therapeutics. 62:417-425

Objective To investigate the effect of steady-state fluconazole administration on the disposition of eprosartan, losartan, and E-3174. Methods Sixteen healthy male subjects received 300 mg eprosartan every 12 hours, and 16 received 100 mg losartan ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c5418e975237a6d78f0ad32058a1a65
https://doi.org/10.1016/s0009-9236(97)90120-x

Zobrazit plný text záznamu

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers

Autor: David Tenero, David E. Martin, Steven C. Boike, D. Tompson, Diane K. Jorkasky, Bernard E. Ilson, David R. Citerone

Publikováno v: British Journal of Clinical Pharmacology. 43:661-664

Summary [mean (s.d.)] pharmacokinetic parameters of digoxin determined in the presence and absence of eprosartan andassociated point estimates and 90% conﬁdence intervals*. Digoxin Digoxin + PointParameter alone eprosartan Comparison estimate 90% C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cbba844b7be41386860a9b86a1fc72b
https://doi.org/10.1046/j.1365-2125.1997.00608.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání